国际标准期刊号: 2155-9872

分析与生物分析技术杂志

开放获取

我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

索引于
  • CAS 来源索引 (CASSI)
  • 哥白尼索引
  • 谷歌学术
  • 夏尔巴·罗密欧
  • 学术期刊数据库
  • 打开 J 门
  • Genamics 期刊搜索
  • 期刊目录
  • 研究圣经
  • 中国知网(CNKI)
  • 乌尔里希的期刊目录
  • 电子期刊图书馆
  • 参考搜索
  • 研究期刊索引目录 (DRJI)
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • OCLC-世界猫
  • 学者指导
  • SWB 在线目录
  • 虚拟生物学图书馆 (vifabio)
  • 普布隆斯
  • 欧洲酒吧
  • ICMJE
分享此页面

抽象的

Real-time Non-invasive Transdermal Monitoring of Photosensitizer Level in vivo for Pharmacokinetic Studies and Optimization of Photodynamic Therapy Protocol

Malgorzata Szczygiel, Bozena Boron, Dariusz Szczygiel, Milena Szafraniec, Anna Susz, Zenon Matuszak, Krystyna Urbanska, Leszek Fiedor and Leszek Fiedor

Efficient application of any therapeutic agent requires the knowledge of the time evolution of drug concentration in tissues. Usually, the collection of such pharmacokinetic data relies on sequential invasive measurements and sacrifice of many animals. Our aim was to establish a non-invasive analytical assay that would allow for determination of the levels of fluorescent (pro)drugs in the tissues. We have applied a portable fiber optics-based spectrophotometric setup to determine pharmacokinetic profiles of two water-soluble chlorophyll derivatives via transdermal emission measurements in vivo, in a model system consisting of DBA/2 mice bearing subcutaneous Cloudman S91 melanoma tumor. Based on their emission spectra, recorded transdermally in real-time, the in vivo peak levels and retention times of intraperitoneally and intravenously administered photosensitizers were estimated. These data served then to optimize the photodynamic therapy protocol. The effects of the treatment show a strong correlation between the efficacy of the therapy and the pharmacokinetic profiles, confirming the validity of the method. This approach has several important advantages, including (i) a maximization of therapeutic effects by indicating the optimal timing for irradiation; (ii) a non-invasive determination of the photosensitizer level in the tumor to predict the therapy outcome; (iii) an estimation of the safety dark period to minimize the side effects related to phototoxicity; (iv) a possibility of performing a whole series of non-invasive pharmacokinetic experiments in the same organism; and (v) a significant cut in the costs of pharmacokinetic studies. The measurements on human tissue indicate that this non-invasive method can be also applied in humans.